Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry
This article was originally published in The Pink Sheet Daily
Executive Summary
As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.